APO Research
Talk to an analyst

APO RESEARCH · REPORT

Glycogen Synthase Kinase 3 Beta

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Glycogen Synthase Kinase 3 Beta Market Outlook and Growth Opportunities 2026

19 December 2025198 pages

Choose your research edition.

Industry ResearchGlycogen Synthase Kinase 3 Beta Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Glycogen Synthase Kinase 3 Beta Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Glycogen Synthase Kinase 3 Beta Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glycogen Synthase Kinase 3 Beta Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Glycogen Synthase Kinase 3 Beta Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Glycogen Synthase Kinase 3 Beta market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Glycogen Synthase Kinase 3 Beta is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Glycogen Synthase Kinase 3 Beta is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Glycogen Synthase Kinase 3 Beta is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Glycogen Synthase Kinase 3 Beta market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Glycogen Synthase Kinase 3 Beta market include Neurim Pharmaceuticals Ltd, Mitsubishi Tanabe Pharma Corp, Jeil Pharmaceutical Co Ltd, DiaMedica Therapeutics Inc, Angelini Group, AMO Pharma Ltd and Actuate Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Glycogen Synthase Kinase 3 Beta market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Glycogen Synthase Kinase 3 Beta and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Glycogen Synthase Kinase 3 Beta sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Glycogen Synthase Kinase 3 Beta market size, projected growth trends, production technologies, key applications, and end-use industries.

Glycogen Synthase Kinase 3 Beta Segment by Company

Neurim Pharmaceuticals Ltd

Mitsubishi Tanabe Pharma Corp

Jeil Pharmaceutical Co Ltd

DiaMedica Therapeutics Inc

Angelini Group

AMO Pharma Ltd

Actuate Therapeutics Inc

Glycogen Synthase Kinase 3 Beta Segment by Type

Neu-120

DM-204

AP-1

AP-001

Others

Glycogen Synthase Kinase 3 Beta Segment by Application

Dyskinesia

Musculoskeletal Disorder

Lung Cancer

Menkes Disease

Others

Glycogen Synthase Kinase 3 Beta Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Glycogen Synthase Kinase 3 Beta status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Glycogen Synthase Kinase 3 Beta market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Glycogen Synthase Kinase 3 Beta significant trends, drivers, influence factors in global and regions.

6. To analyze Glycogen Synthase Kinase 3 Beta competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glycogen Synthase Kinase 3 Beta market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glycogen Synthase Kinase 3 Beta and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glycogen Synthase Kinase 3 Beta.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Glycogen Synthase Kinase 3 Beta market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Glycogen Synthase Kinase 3 Beta industry.

Chapter 3: Detailed analysis of Glycogen Synthase Kinase 3 Beta manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Glycogen Synthase Kinase 3 Beta in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Glycogen Synthase Kinase 3 Beta in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Glycogen Synthase Kinase 3 Beta Industry Trends Table 2. Glycogen Synthase Kinase 3 Beta Industry Drivers Table 3. Glycogen Synthase Kinase 3 Beta Industry Opportunities and Challenges Table 4. Glycogen Synthase Kinase 3 Beta Industry Restraints Table 5. Global Glycogen Synthase Kinase 3 Beta Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Glycogen Synthase Kinase 3 Beta Revenue Share by Company (2021-2026) Table 7. Global Glycogen Synthase Kinase 3 Beta Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Glycogen Synthase Kinase 3 Beta Sales Volume Share by Company (2021-2026) Table 9. Global Glycogen Synthase Kinase 3 Beta Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Glycogen Synthase Kinase 3 Beta Company Ranking, (2024-2026) & (USD Million) Table 11. Global Glycogen Synthase Kinase 3 Beta Key Company Manufacturing Base & Headquarters Table 12. Global Glycogen Synthase Kinase 3 Beta Company, Product Type & Application Table 13. Global Glycogen Synthase Kinase 3 Beta Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Glycogen Synthase Kinase 3 Beta by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Neu-120 Table 18. Significant Companies of DM-204 Table 19. Significant Companies of AP-1 Table 20. Significant Companies of AP-001 Table 21. Significant Companies of Others Table 22. Global Glycogen Synthase Kinase 3 Beta Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Glycogen Synthase Kinase 3 Beta Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Glycogen Synthase Kinase 3 Beta Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Glycogen Synthase Kinase 3 Beta Sales Volume Share by Type (2021-2026) Table 26. Global Glycogen Synthase Kinase 3 Beta Sales Volume Share by Type (2027-2032) Table 27. Global Glycogen Synthase Kinase 3 Beta Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Glycogen Synthase Kinase 3 Beta Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Glycogen Synthase Kinase 3 Beta Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Glycogen Synthase Kinase 3 Beta Sales Value Share by Type (2021-2026) Table 31. Global Glycogen Synthase Kinase 3 Beta Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Dyskinesia Table 33. Significant Companies of Musculoskeletal Disorder Table 34. Significant Companies of Lung Cancer Table 35. Significant Companies of Menkes Disease Table 36. Significant Companies of Others Table 37. Global Glycogen Synthase Kinase 3 Beta Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Glycogen Synthase Kinase 3 Beta Sales Volume by Application (2021-2026) & (K Units) Table 39. Global Glycogen Synthase Kinase 3 Beta Sales Volume by Application (2027-2032) & (K Units) Table 40. Global Glycogen Synthase Kinase 3 Beta Sales Volume Share by Application (2021-2026) Table 41. Global Glycogen Synthase Kinase 3 Beta Sales Volume Share by Application (2027-2032) Table 42. Global Glycogen Synthase Kinase 3 Beta Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Glycogen Synthase Kinase 3 Beta Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Glycogen Synthase Kinase 3 Beta Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Glycogen Synthase Kinase 3 Beta Sales Value Share by Application (2021-2026) Table 46. Global Glycogen Synthase Kinase 3 Beta Sales Value Share by Application (2027-2032) Table 47. Global Glycogen Synthase Kinase 3 Beta Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global Glycogen Synthase Kinase 3 Beta Sales by Region (2021-2026) & (K Units) Table 49. Global Glycogen Synthase Kinase 3 Beta Sales Market Share by Region (2021-2026) Table 50. Global Glycogen Synthase Kinase 3 Beta Sales by Region (2027-2032) & (K Units) Table 51. Global Glycogen Synthase Kinase 3 Beta Sales Market Share by Region (2027-2032) Table 52. Global Glycogen Synthase Kinase 3 Beta Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Glycogen Synthase Kinase 3 Beta Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Glycogen Synthase Kinase 3 Beta Sales Value Share by Region (2021-2026) Table 55. Global Glycogen Synthase Kinase 3 Beta Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Glycogen Synthase Kinase 3 Beta Sales Value Share by Region (2027-2032) Table 57. Global Glycogen Synthase Kinase 3 Beta Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Glycogen Synthase Kinase 3 Beta Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Glycogen Synthase Kinase 3 Beta Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Global Glycogen Synthase Kinase 3 Beta Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Glycogen Synthase Kinase 3 Beta Sales by Country (2021-2026) & (K Units) Table 62. Global Glycogen Synthase Kinase 3 Beta Sales Market Share by Country (2021-2026) Table 63. Global Glycogen Synthase Kinase 3 Beta Sales by Country (2027-2032) & (K Units) Table 64. Global Glycogen Synthase Kinase 3 Beta Sales Market Share by Country (2027-2032) Table 65. Global Glycogen Synthase Kinase 3 Beta Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Glycogen Synthase Kinase 3 Beta Sales Value Market Share by Country (2021-2026) Table 67. Global Glycogen Synthase Kinase 3 Beta Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Glycogen Synthase Kinase 3 Beta Sales Value Market Share by Country (2027-2032) Table 69. Neurim Pharmaceuticals Ltd Company Information Table 70. Neurim Pharmaceuticals Ltd Business Overview Table 71. Neurim Pharmaceuticals Ltd Glycogen Synthase Kinase 3 Beta Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Neurim Pharmaceuticals Ltd Glycogen Synthase Kinase 3 Beta Product Portfolio Table 73. Neurim Pharmaceuticals Ltd Recent Development Table 74. Mitsubishi Tanabe Pharma Corp Company Information Table 75. Mitsubishi Tanabe Pharma Corp Business Overview Table 76. Mitsubishi Tanabe Pharma Corp Glycogen Synthase Kinase 3 Beta Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Mitsubishi Tanabe Pharma Corp Glycogen Synthase Kinase 3 Beta Product Portfolio Table 78. Mitsubishi Tanabe Pharma Corp Recent Development Table 79. Jeil Pharmaceutical Co Ltd Company Information Table 80. Jeil Pharmaceutical Co Ltd Business Overview Table 81. Jeil Pharmaceutical Co Ltd Glycogen Synthase Kinase 3 Beta Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Jeil Pharmaceutical Co Ltd Glycogen Synthase Kinase 3 Beta Product Portfolio Table 83. Jeil Pharmaceutical Co Ltd Recent Development Table 84. DiaMedica Therapeutics Inc Company Information Table 85. DiaMedica Therapeutics Inc Business Overview Table 86. DiaMedica Therapeutics Inc Glycogen Synthase Kinase 3 Beta Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. DiaMedica Therapeutics Inc Glycogen Synthase Kinase 3 Beta Product Portfolio Table 88. DiaMedica Therapeutics Inc Recent Development Table 89. Angelini Group Company Information Table 90. Angelini Group Business Overview Table 91. Angelini Group Glycogen Synthase Kinase 3 Beta Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Angelini Group Glycogen Synthase Kinase 3 Beta Product Portfolio Table 93. Angelini Group Recent Development Table 94. AMO Pharma Ltd Company Information Table 95. AMO Pharma Ltd Business Overview Table 96. AMO Pharma Ltd Glycogen Synthase Kinase 3 Beta Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. AMO Pharma Ltd Glycogen Synthase Kinase 3 Beta Product Portfolio Table 98. AMO Pharma Ltd Recent Development Table 99. Actuate Therapeutics Inc Company Information Table 100. Actuate Therapeutics Inc Business Overview Table 101. Actuate Therapeutics Inc Glycogen Synthase Kinase 3 Beta Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Actuate Therapeutics Inc Glycogen Synthase Kinase 3 Beta Product Portfolio Table 103. Actuate Therapeutics Inc Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Glycogen Synthase Kinase 3 Beta Distributors List Table 107. Glycogen Synthase Kinase 3 Beta Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Glycogen Synthase Kinase 3 Beta Product Image Figure 2. Global Glycogen Synthase Kinase 3 Beta Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Glycogen Synthase Kinase 3 Beta Sales Value (2021-2032) & (US$ Million) Figure 4. Global Glycogen Synthase Kinase 3 Beta Sales (2021-2032) & (K Units) Figure 5. Global Glycogen Synthase Kinase 3 Beta Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Glycogen Synthase Kinase 3 Beta Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Neu-120 Image Figure 10. DM-204 Image Figure 11. AP-1 Image Figure 12. AP-001 Image Figure 13. Others Image Figure 14. Global Glycogen Synthase Kinase 3 Beta Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Glycogen Synthase Kinase 3 Beta Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Glycogen Synthase Kinase 3 Beta Sales Volume Share by Type (2021-2032) Figure 17. Global Glycogen Synthase Kinase 3 Beta Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Glycogen Synthase Kinase 3 Beta Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Glycogen Synthase Kinase 3 Beta Sales Value Share by Type (2021-2032) Figure 20. Dyskinesia Image Figure 21. Musculoskeletal Disorder Image Figure 22. Lung Cancer Image Figure 23. Menkes Disease Image Figure 24. Others Image Figure 25. Global Glycogen Synthase Kinase 3 Beta Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Glycogen Synthase Kinase 3 Beta Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Glycogen Synthase Kinase 3 Beta Sales Volume Share by Application (2021-2032) Figure 28. Global Glycogen Synthase Kinase 3 Beta Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Glycogen Synthase Kinase 3 Beta Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Glycogen Synthase Kinase 3 Beta Sales Value Share by Application (2021-2032) Figure 31. Global Glycogen Synthase Kinase 3 Beta Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 32. Global Glycogen Synthase Kinase 3 Beta Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Glycogen Synthase Kinase 3 Beta Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Glycogen Synthase Kinase 3 Beta Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Glycogen Synthase Kinase 3 Beta Sales Value (2021-2032) & (US$ Million) Figure 36. North America Glycogen Synthase Kinase 3 Beta Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Glycogen Synthase Kinase 3 Beta Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Glycogen Synthase Kinase 3 Beta Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Glycogen Synthase Kinase 3 Beta Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Glycogen Synthase Kinase 3 Beta Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Glycogen Synthase Kinase 3 Beta Sales Value (2021-2032) & (US$ Million) Figure 42. South America Glycogen Synthase Kinase 3 Beta Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Glycogen Synthase Kinase 3 Beta Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Glycogen Synthase Kinase 3 Beta Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Glycogen Synthase Kinase 3 Beta Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Glycogen Synthase Kinase 3 Beta Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Neu-120
  • DM-204
  • AP-1
  • AP-001
  • Others
Applications
  • Dyskinesia
  • Musculoskeletal Disorder
  • Lung Cancer
  • Menkes Disease
  • Others
Companies covered
  • Neurim Pharmaceuticals Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Jeil Pharmaceutical Co Ltd
  • DiaMedica Therapeutics Inc
  • Angelini Group
  • AMO Pharma Ltd
  • Actuate Therapeutics Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Glycogen Synthase Kinase 3 Beta Sales Value (2021-2032)
  4. 1.2.2 Global Glycogen Synthase Kinase 3 Beta Sales Volume (2021-2032)
  5. 1.2.3 Global Glycogen Synthase Kinase 3 Beta Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Glycogen Synthase Kinase 3 Beta Market Dynamics
  1. 2.1 Glycogen Synthase Kinase 3 Beta Industry Trends
  2. 2.2 Glycogen Synthase Kinase 3 Beta Industry Drivers
  3. 2.3 Glycogen Synthase Kinase 3 Beta Industry Opportunities and Challenges
  4. 2.4 Glycogen Synthase Kinase 3 Beta Industry Restraints
3 Glycogen Synthase Kinase 3 Beta Market by Company
  1. 3.1 Global Glycogen Synthase Kinase 3 Beta Company Revenue Ranking in 2025
  2. 3.2 Global Glycogen Synthase Kinase 3 Beta Revenue by Company (2021-2026)
  3. 3.3 Global Glycogen Synthase Kinase 3 Beta Sales Volume by Company (2021-2026)
  4. 3.4 Global Glycogen Synthase Kinase 3 Beta Average Price by Company (2021-2026)
  5. 3.5 Global Glycogen Synthase Kinase 3 Beta Company Ranking (2024-2026)
  6. 3.6 Global Glycogen Synthase Kinase 3 Beta Company Manufacturing Base and Headquarters
  7. 3.7 Global Glycogen Synthase Kinase 3 Beta Company Product Type and Application
  8. 3.8 Global Glycogen Synthase Kinase 3 Beta Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Glycogen Synthase Kinase 3 Beta Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Glycogen Synthase Kinase 3 Beta Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Glycogen Synthase Kinase 3 Beta Market by Type
  1. 4.1 Glycogen Synthase Kinase 3 Beta Type Introduction
  2. 4.1.1 Neu-120
  3. 4.1.2 DM-204
  4. 4.1.3 AP-1
  5. 4.1.4 AP-001
  6. 4.1.5 Others
  7. 4.2 Global Glycogen Synthase Kinase 3 Beta Sales Volume by Type
  8. 4.2.1 Global Glycogen Synthase Kinase 3 Beta Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Glycogen Synthase Kinase 3 Beta Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Glycogen Synthase Kinase 3 Beta Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Glycogen Synthase Kinase 3 Beta Sales Value by Type
  12. 4.3.1 Global Glycogen Synthase Kinase 3 Beta Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Glycogen Synthase Kinase 3 Beta Sales Value by Type (2021-2032)
  14. 4.3.3 Global Glycogen Synthase Kinase 3 Beta Sales Value Share by Type (2021-2032)
5 Glycogen Synthase Kinase 3 Beta Market by Application
  1. 5.1 Glycogen Synthase Kinase 3 Beta Application Introduction
  2. 5.1.1 Dyskinesia
  3. 5.1.2 Musculoskeletal Disorder
  4. 5.1.3 Lung Cancer
  5. 5.1.4 Menkes Disease
  6. 5.1.5 Others
  7. 5.2 Global Glycogen Synthase Kinase 3 Beta Sales Volume by Application
  8. 5.2.1 Global Glycogen Synthase Kinase 3 Beta Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Glycogen Synthase Kinase 3 Beta Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Glycogen Synthase Kinase 3 Beta Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Glycogen Synthase Kinase 3 Beta Sales Value by Application
  12. 5.3.1 Global Glycogen Synthase Kinase 3 Beta Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Glycogen Synthase Kinase 3 Beta Sales Value by Application (2021-2032)
  14. 5.3.3 Global Glycogen Synthase Kinase 3 Beta Sales Value Share by Application (2021-2032)
6 Glycogen Synthase Kinase 3 Beta Regional Sales and Value Analysis
  1. 6.1 Global Glycogen Synthase Kinase 3 Beta Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Glycogen Synthase Kinase 3 Beta Sales by Region (2021-2032)
  3. 6.2.1 Global Glycogen Synthase Kinase 3 Beta Sales by Region: 2021-2026
  4. 6.2.2 Global Glycogen Synthase Kinase 3 Beta Sales by Region (2027-2032)
  5. 6.3 Global Glycogen Synthase Kinase 3 Beta Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Glycogen Synthase Kinase 3 Beta Sales Value by Region (2021-2032)
  7. 6.4.1 Global Glycogen Synthase Kinase 3 Beta Sales Value by Region: 2021-2026
  8. 6.4.2 Global Glycogen Synthase Kinase 3 Beta Sales Value by Region (2027-2032)
  9. 6.5 Global Glycogen Synthase Kinase 3 Beta Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Glycogen Synthase Kinase 3 Beta Sales Value (2021-2032)
  12. 6.6.2 North America Glycogen Synthase Kinase 3 Beta Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Glycogen Synthase Kinase 3 Beta Sales Value (2021-2032)
  15. 6.7.2 Europe Glycogen Synthase Kinase 3 Beta Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Glycogen Synthase Kinase 3 Beta Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Glycogen Synthase Kinase 3 Beta Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Glycogen Synthase Kinase 3 Beta Sales Value (2021-2032)
  21. 6.9.2 South America Glycogen Synthase Kinase 3 Beta Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Glycogen Synthase Kinase 3 Beta Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Glycogen Synthase Kinase 3 Beta Sales Value Share by Country, 2025 VS 2032
7 Glycogen Synthase Kinase 3 Beta Country-level Sales and Value Analysis
  1. 7.1 Global Glycogen Synthase Kinase 3 Beta Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Glycogen Synthase Kinase 3 Beta Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Glycogen Synthase Kinase 3 Beta Sales by Country (2021-2032)
  4. 7.3.1 Global Glycogen Synthase Kinase 3 Beta Sales by Country (2021-2026)
  5. 7.3.2 Global Glycogen Synthase Kinase 3 Beta Sales by Country (2027-2032)
  6. 7.4 Global Glycogen Synthase Kinase 3 Beta Sales Value by Country (2021-2032)
  7. 7.4.1 Global Glycogen Synthase Kinase 3 Beta Sales Value by Country (2021-2026)
  8. 7.4.2 Global Glycogen Synthase Kinase 3 Beta Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Glycogen Synthase Kinase 3 Beta Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Glycogen Synthase Kinase 3 Beta Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Glycogen Synthase Kinase 3 Beta Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Neurim Pharmaceuticals Ltd
  2. 8.1.1 Neurim Pharmaceuticals Ltd Company Information
  3. 8.1.2 Neurim Pharmaceuticals Ltd Business Overview
  4. 8.1.3 Neurim Pharmaceuticals Ltd Glycogen Synthase Kinase 3 Beta Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Neurim Pharmaceuticals Ltd Glycogen Synthase Kinase 3 Beta Product Portfolio
  6. 8.1.5 Neurim Pharmaceuticals Ltd Recent Developments
  7. 8.2 Mitsubishi Tanabe Pharma Corp
  8. 8.2.1 Mitsubishi Tanabe Pharma Corp Company Information
  9. 8.2.2 Mitsubishi Tanabe Pharma Corp Business Overview
  10. 8.2.3 Mitsubishi Tanabe Pharma Corp Glycogen Synthase Kinase 3 Beta Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Mitsubishi Tanabe Pharma Corp Glycogen Synthase Kinase 3 Beta Product Portfolio
  12. 8.2.5 Mitsubishi Tanabe Pharma Corp Recent Developments
  13. 8.3 Jeil Pharmaceutical Co Ltd
  14. 8.3.1 Jeil Pharmaceutical Co Ltd Company Information
  15. 8.3.2 Jeil Pharmaceutical Co Ltd Business Overview
  16. 8.3.3 Jeil Pharmaceutical Co Ltd Glycogen Synthase Kinase 3 Beta Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Jeil Pharmaceutical Co Ltd Glycogen Synthase Kinase 3 Beta Product Portfolio
  18. 8.3.5 Jeil Pharmaceutical Co Ltd Recent Developments
  19. 8.4 DiaMedica Therapeutics Inc
  20. 8.4.1 DiaMedica Therapeutics Inc Company Information
  21. 8.4.2 DiaMedica Therapeutics Inc Business Overview
  22. 8.4.3 DiaMedica Therapeutics Inc Glycogen Synthase Kinase 3 Beta Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 DiaMedica Therapeutics Inc Glycogen Synthase Kinase 3 Beta Product Portfolio
  24. 8.4.5 DiaMedica Therapeutics Inc Recent Developments
  25. 8.5 Angelini Group
  26. 8.5.1 Angelini Group Company Information
  27. 8.5.2 Angelini Group Business Overview
  28. 8.5.3 Angelini Group Glycogen Synthase Kinase 3 Beta Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Angelini Group Glycogen Synthase Kinase 3 Beta Product Portfolio
  30. 8.5.5 Angelini Group Recent Developments
  31. 8.6 AMO Pharma Ltd
  32. 8.6.1 AMO Pharma Ltd Company Information
  33. 8.6.2 AMO Pharma Ltd Business Overview
  34. 8.6.3 AMO Pharma Ltd Glycogen Synthase Kinase 3 Beta Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AMO Pharma Ltd Glycogen Synthase Kinase 3 Beta Product Portfolio
  36. 8.6.5 AMO Pharma Ltd Recent Developments
  37. 8.7 Actuate Therapeutics Inc
  38. 8.7.1 Actuate Therapeutics Inc Company Information
  39. 8.7.2 Actuate Therapeutics Inc Business Overview
  40. 8.7.3 Actuate Therapeutics Inc Glycogen Synthase Kinase 3 Beta Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Actuate Therapeutics Inc Glycogen Synthase Kinase 3 Beta Product Portfolio
  42. 8.7.5 Actuate Therapeutics Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Glycogen Synthase Kinase 3 Beta Value Chain Analysis
  2. 9.1.1 Glycogen Synthase Kinase 3 Beta Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Glycogen Synthase Kinase 3 Beta Sales Mode & Process
  6. 9.2 Glycogen Synthase Kinase 3 Beta Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Glycogen Synthase Kinase 3 Beta Distributors
  9. 9.2.3 Glycogen Synthase Kinase 3 Beta Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst